A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors — Stella
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(29 sites)
United States
City of Hope Cancer Center, Duarte, California
City of Hope at Irvine Lennar, Irvine, California
Emory University School of Medicine, Atlanta, Georgia
Norton Cancer Institute - MDC, Louisville, Kentucky
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Duke University, Durham, North Carolina
Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma
SCRI Oncology Partners, Nashville, Tennessee
MD Anderson Cancer Center, Houston, Texas
Australia
St Vincents Sydney, Darlinghurst, New South Wales
Alfred Hospital, Melbourne, Victoria
Belgium
UZ Leuven Gasthuisberg, Leuven
Canada
BCCA-Vancouver Cancer Centre, Vancouver, British Columbia
Princess Margaret Cancer Center, Toronto, Ontario
Denmark
Rigshospitalet, København Ø
France
CLCC Leon Berard Lyon, Lyon
Gustave Roussy, Villejuif
Malaysia
Sarawak Public Hospital, Kuching, Sarawak
South Korea
Seoul National University Bundang Hospital, Seongnam-si
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Spain
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, BARCELONA
Clinica Universidad de Navarra Madrid, Madrid, Madrid
START Madrid. Centro Integral Oncologico Clara Campal, Madrid, Madrid
Clinica Universitaria de Navarra, Pamplona, Navarre
Hospital Clinico Universitario de Valencia, Valencia, Valencia